Equities Analysts Issue Forecasts for PBH Q3 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Analysts at DA Davidson issued their Q3 2025 earnings per share estimates for Prestige Consumer Healthcare in a report released on Monday, November 11th. DA Davidson analyst L. Weiser expects that the company will earn $1.16 per share for the quarter. DA Davidson has a "Buy" rating and a $95.00 price target on the stock. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.44 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare's FY2025 earnings at $4.46 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, hitting the consensus estimate of $1.09. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business had revenue of $283.79 million during the quarter, compared to analysts' expectations of $282.09 million. During the same quarter last year, the firm posted $1.07 earnings per share. The firm's revenue was down .9% on a year-over-year basis.

Separately, Jefferies Financial Group reaffirmed a "hold" rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $94.20.

Prestige Consumer Healthcare Stock Up 0.4 %

Shares of PBH stock traded up $0.31 on Tuesday, reaching $82.06. 252,782 shares of the company were exchanged, compared to its average volume of 248,120. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 1.90. The company has a 50-day moving average of $72.69 and a 200-day moving average of $69.92. The company has a market cap of $4.05 billion, a price-to-earnings ratio of 20.00, a PEG ratio of 2.27 and a beta of 0.47. Prestige Consumer Healthcare has a one year low of $56.61 and a one year high of $82.82.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors have recently added to or reduced their stakes in the business. Opal Wealth Advisors LLC bought a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $26,000. Quest Partners LLC boosted its stake in shares of Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company's stock valued at $30,000 after purchasing an additional 424 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Prestige Consumer Healthcare by 80.6% in the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock worth $33,000 after purchasing an additional 208 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock valued at $35,000 after buying an additional 433 shares during the last quarter. Finally, Gladius Capital Management LP purchased a new position in shares of Prestige Consumer Healthcare in the second quarter valued at about $35,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.